CORE--TISSUE PROCUREMENT AND GENETICS

我们推测，围绕着一个整合的组织学和分子诊断实验室组织的组织库，以及从不断更新的数据库中获得的所有研究和临床信息，是该孢子成功的关键因素。 为了验证这一假设，我们提出了以下4个具体目标： (1)向孢子内的程序和研究人员提供来自肿瘤脑的DNA、RNA和组织，以及来自正常血液、脑和其他身体部位的DNA、RNA、组织和血清，以使其能够在孢子组织委员会的监督下用于各种研究和技术； (2)应用综合组织库/临床数据信息学系统，以便在组织委员会的监督下，根据共同的人口统计数据、临床数据、组织诊断和/或成像研究快速确定患者群体，并有效地管理和分析研究结果和临床结果的数据； (3)对保存的样本进行分子遗传学、分子细胞遗传学和组织学分析，以检测分类、分级和治疗反应的标记，并将这些发现转化为临床试验，所有项目均在该孢子中进行。 (4)从分子、细胞和组织水平对在该孢子中发现的标志物进行定性和定量评估，以便将这些基本发现转化为临床试验。首先，我们将描述恶性脑胶质瘤中瘤内和瘤间的异质性，以及烷基鸟嘌呤转移酶、新发现的肿瘤胶质细胞表面标志物MRP3、EGFR和EGFRvIII、谷胱甘肽S转移酶P1和巨细胞病毒抗原pp65的免疫反应在诊断和预后方面的意义。

We hypothesize that a tissue bank organized around an integrated histologic and molecular diagnostic laboratory with all research and clinical information available from a constantly updated database is an essential element to the success of this SPORE. To test this hypothesis we propose the following 4 Specific Aims: (1) to provide DNA, RNA, and tissue from neoplastic brain as well as DNA, RNA, tissue, and serum from normal blood, brain, and other body sites to programs and investigators within the SPORE, in a manner in which they can be used for a variety of studies and techniques under the oversight of the SPORE Tissue Committee; (2) to apply an integrated tissue bank/clinical data informatics system that allows the rapid identification of patient groups based on common demographics, clinical data, tissue diagnoses, and/or imaging studies and the efficient management and analysis of data from research results and clinical outcome under the oversight of a Tissue Committee; (3) to provide molecular genetic, molecular cytogenetic, and histologie analysis of banked samples in order to detect markers of classification, grading, and therapeutic response and to translate these findings into clinical trials with all projects in this SPORE. (4) to provide qualitative and quantitative assessments at the molecular, cellular, and histologic level of markers discovered in this SPORE for the translation of these basic discoveries into clinical trials. Initially we will characterize intratumoral and intertumoral heterogeneity and the diagnostic and prognostic significance of immunoreactivity for alkylguanine transferase (AGT), for the newly identified tumor glial cell surface markers MRP3, EGFR, and EGFRvIII, for glutathione S-transferase P1 (GSTP1) and for CMV antigen, pp65, in malignant human gliomas.